Lynnwood, WA

RSS
Twitter
Facebook
Email
LinkedIn

About PTx
Products
- BIZENGRI^® (zenocutuzumab-zbco)
- LEUKINE^® (sargramostim)
Research
Medical Info
- Medical Inquiries
Contact Us

Lynnwood, WA Site

Mailing Address

2625 162nd St SW,
Lynnwood, WA 98087

Latest News

New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI^®) in NRG1+ cancer
...
BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis
...
Merus Announces FDA Approval of BIZENGRI^® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
...

Join Our Team

Partner Therapeutics (PTx) is a commercial biotech committed to improving the lives of patients with cancer and other serious diseases. We're looking for passionate professionals to join us with expertise that spans the biopharma value chain.

View Current Openings

Home
News
Privacy Policy
Terms of Use

Lynnwood, WA Site

Mailing Address

New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer

BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI^®) in NRG1+ cancer

Merus Announces FDA Approval of BIZENGRI^® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study